CN113166248A - 人源化抗人ox40单克隆抗体及其制备方法和用途 - Google Patents

人源化抗人ox40单克隆抗体及其制备方法和用途 Download PDF

Info

Publication number
CN113166248A
CN113166248A CN201980077176.8A CN201980077176A CN113166248A CN 113166248 A CN113166248 A CN 113166248A CN 201980077176 A CN201980077176 A CN 201980077176A CN 113166248 A CN113166248 A CN 113166248A
Authority
CN
China
Prior art keywords
variable region
seq
chain variable
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980077176.8A
Other languages
English (en)
Other versions
CN113166248B (zh
Inventor
殷刘松
周铁林
蒋忻坡
方卓
米艳玲
吴瑃辰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN113166248A publication Critical patent/CN113166248A/zh
Application granted granted Critical
Publication of CN113166248B publication Critical patent/CN113166248B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明涉及一种人源化抗人OX40单克隆抗体及其制备方法和用途。本发明提供的人源化抗人OX40单克隆抗体对OX40具有高亲和性、高特异性，能够刺激T细胞分泌细胞因子，例如特异地激活OX40的免疫正调节，激活T细胞分泌细胞因子。因而，本发明提供的功能性人源化抗人OX40单克隆抗体，可通过激活OX40信号通路来激活T细胞，进而实现肿瘤免疫治疗的目的。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980077176.8A 2018-11-26 2019-11-26 人源化抗人ox40单克隆抗体及其制备方法和用途 Active CN113166248B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811420381 2018-11-26
CN2018114203813 2018-11-26
PCT/CN2019/120808 WO2020108463A1 (zh) 2018-11-26 2019-11-26 人源化抗人ox40单克隆抗体及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113166248A true CN113166248A (zh) 2021-07-23
CN113166248B CN113166248B (zh) 2022-05-27

Family

ID=70853818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980077176.8A Active CN113166248B (zh) 2018-11-26 2019-11-26 人源化抗人ox40单克隆抗体及其制备方法和用途

Country Status (4)

Country Link
US (1) US20220119540A1 (zh)
EP (1) EP3889180A4 (zh)
CN (1) CN113166248B (zh)
WO (1) WO2020108463A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651883A (zh) * 2021-08-04 2021-11-16 广州呼研所医药科技有限公司 人源化抗HAdV-B7单克隆中和抗体、制备方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用
CN112794907B (zh) * 2020-12-03 2022-09-06 安徽安科生物工程（集团）股份有限公司 一株全人源抗人huOX40单克隆抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103486A (zh) * 2014-03-31 2016-11-09 豪夫迈·罗氏有限公司 抗ox40抗体和使用方法
CN107074953A (zh) * 2014-10-10 2017-08-18 免疫医疗有限责任公司 人源化抗ox40抗体及其用途
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018107693A (ru) * 2015-08-04 2019-09-05 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Комбинированные виды лечения и их варианты применения и способы
CN109232738B (zh) * 2017-07-11 2021-11-09 南京金斯瑞生物科技有限公司 一种抗人ox40单克隆抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103486A (zh) * 2014-03-31 2016-11-09 豪夫迈·罗氏有限公司 抗ox40抗体和使用方法
CN107074953A (zh) * 2014-10-10 2017-08-18 免疫医疗有限责任公司 人源化抗ox40抗体及其用途
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651883A (zh) * 2021-08-04 2021-11-16 广州呼研所医药科技有限公司 人源化抗HAdV-B7单克隆中和抗体、制备方法及其应用
CN113651883B (zh) * 2021-08-04 2022-06-10 广州呼研所医药科技有限公司 人源化抗HAdV-B7单克隆中和抗体、制备方法及其应用

Also Published As

Publication number Publication date
US20220119540A1 (en) 2022-04-21
EP3889180A4 (en) 2023-01-04
CN113166248B (zh) 2022-05-27
EP3889180A1 (en) 2021-10-06
WO2020108463A1 (zh) 2020-06-04

Similar Documents

Publication Publication Date Title
ES2819870T3 (es) Moléculas de unión con cadena J modificada
CN106687479B (zh) 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
CN113166248B (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
JP7373650B2 (ja) 抗ｐｄ－ｌ１シングルドメイン抗体
BR112020021269A2 (pt) Construções de anticorpo anti-ror
CN111201243B (zh) 对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物
TW201932491A (zh) 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
WO2016127104A2 (en) Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
JP2021519088A (ja) 抗ｃｄ２７抗体、その抗原結合フラグメント及びその医学的使用
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN109627340B (zh) Cd3和prlr双特异性抗体及其构建与应用
JP2018506296A (ja) Ｉｌ−１７ｃに対する抗体
CN114364400A (zh) 使用pd-1轴抑制剂及抗骨膜蛋白抗体治疗癌症的方法
CN112513084B (zh) 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN113039207B (zh) 人源化抗人pd-l1单克隆抗体及其制备方法和用途
WO2018101425A1 (ja) 抗ｔｌｒ９抗体、医薬組成物及びキット
CN114761434B (zh) Pd-1抗体及其制备方法与应用
KR102550094B1 (ko) 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도
TW202144425A (zh) 特異性抗原結合分子，其製備方法及醫藥用途
CN116284406A (zh) 一种pd-1结合蛋白及其应用
CN114729051A (zh) 使用抗ox40抗体与放射组合治疗癌症的方法
CN114901695A (zh) 抗gitr抗体及其用途
KR20120092767A (ko) 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210723

Assignee: Nanjing vigorous Biotechnology Co.,Ltd.

Assignor: NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY Corp.

Contract record no.: X2023990000153

Denomination of invention: Humanized anti-human OX40 monoclonal antibody and its preparation method and use

Granted publication date: 20220527

License type: Exclusive License

Record date: 20230116